Rifapentine access in Europe: growing concerns over key tuberculosis treatment component.

Authors :: Guglielmetti L
Günther G
Leu C
Cirillo D
Duarte R
Garcia-Basteiro AL
Goletti D
Jankovic M
Kuksa L
Maurer FP
Méchaï F
Tiberi S
van Leth F
Veziris N
Lange C
Source :: The European respiratory journal [Eur Respir J] 2022 May 19; Vol. 59 (5). Date of Electronic Publication: 2022 May 19 (Print Publication: 2022).
Publication Year :: 2022
Abstract: Competing Interests: Conflict of interest: L. Guglielmetti is the co-principal investigator of two MSF-sponsored clinical trials testing shorter MDR-TB regimens, and has no other competing interests to disclose. All other authors have no competing interests.

Subjects :: Antitubercular Agents therapeutic use
Drug Therapy, Combination
Europe
Humans
Rifampin analogs & derivatives
Rifampin therapeutic use
Antibiotics, Antitubercular therapeutic use
Tuberculosis drug therapy
Tuberculosis epidemiology

Full Text Access

Tools